Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about Drug: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No AI portrait yet
Knowledge base pages for this entity
| Target | Relation | Type | Str |
|---|---|---|---|
| Photoreceptor | causes | cell_type | 0.95 |
| Photoreceptor Degeneration | causes | phenotype | 0.95 |
| Retinal Pigment Epithelium | causes | cell_type | 0.95 |
| Ganglion Cell | causes | cell_type | 0.95 |
| Optic Nerve | causes | cell_type | 0.90 |
| Ganglion Cell Damage | causes | phenotype | 0.90 |
| Uveitis | causes | disease | 0.90 |
| Source | Relation | Type | Str |
|---|---|---|---|
| No incoming edges | |||
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| STING Antagonists as ALS Therapeutics: Drug Repurposing | 0.740 | neuroinflammation | How does chronic cGAS/STING activation d |
| Pharmacogenomic CNS Drug Optimization Platform | 0.611 | neurodegeneration | How do neurodegeneration gene expression |
| MALAT1 Three-Way Junction as a Druggable Target for Structur | 0.587 | molecular biology | What are the conserved secondary structu |
| Brain-Ester Prodrug Strategy for CNS-Selective HDAC6 Inhibit | 0.570 | pharmacology | How can CNS-selective HDAC/DNMT inhibito |
| MFSD2A-Targeted Lysophosphatidylcholine-SPM Conjugates as CN | 0.552 | neuropharmacology | What determines blood-brain barrier pene |
| Kinase Inhibitor-C1q Structural Convergence for Bifunctional | 0.458 | neuroinflammation | How does Alectinib, a kinase inhibitor, |
| IGFBPL1 Peptide Mimetics for Drug-Like BBB Permeability | 0.420 | drug delivery | Can IGFBPL1 therapeutics effectively cro |
| Cathepsin-Dependent Processing of Pro-Drug Enzymes | 0.400 | neurodegeneration | How does controlled lysosomal membrane p |
Scientific analyses that reference this entity
No analyses mention this entity
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| No experiments found | |||||||
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Activation of stimulator of interferon genes (STING) and inhibition of vascular [PMID:41380972] | Wang Y, Hou Y, Han J, Zhang Z, Cheng Y e | J Biol Chem | 2026 | 0 |
| cGAS-STING signaling in Alzheimer's disease: Microglial mechanisms and therapeut [PMID:41481960] | Fazal F, Dar NJ, Ahamad S, Khan S, Bano | Mol Aspects Med | 2026 | 0 |
| Opportunities and challenges of targeting cGAS-STING in cancer. [PMID:41486397] | Lu C, Wang W, Fu YX | Nat Rev Cancer | 2026 | 0 |
| cGAS-STING activation in Parkinson's Disease: From mechanisms to Disease-Modifyi [PMID:41500413] | Solomon J, Mandal S, Aran KR | Gene | 2026 | 0 |
| STING-NF-κB signaling builds an influenza spillover barrier. [PMID:41747053] | Ye R, Wang S, Hu Y, Pan Y, Zheng W et al | Science | 2026 | 0 |
| The cGAS-STING signaling pathway: A central regulator and novel therapeutic targ [PMID:41765111] | Jiang H, Ji Y, Shang T, Qi L, Li Z et al | Biochem Pharmacol | 2026 | 0 |
| cGAS-STING and PANoptosis: Interplay, Underlying Mechanisms, and Therapeutic Tar [PMID:42016387] | Wang Y, Chen J, Feng W, Li N, Zhang X et | Drug Des Devel Ther | 2026 | 0 |
Multi-agent debates referencing this entity
No debates reference this entity
Hypotheses and analyses mentioning Drug in their description or question text
Score: 0.458 · neuroinflammation · 2026-04-16
## Mechanistic Overview Kinase Inhibitor-C1q Structural Convergence for Bifunctional Drug Design starts from the claim t
Score: 0.420 · drug delivery · 2026-04-22
## Mechanistic Overview IGFBPL1 Peptide Mimetics for Drug-Like BBB Permeability starts from the claim that modulating IG
Score: 0.400 · neurodegeneration · 2026-04-21
## Mechanistic Overview Cathepsin-Dependent Processing of Pro-Drug Enzymes starts from the claim that modulating CTSD, U